ABEONA THERAPEUTICS INC. Increase (Decrease) in Due to Related Parties
ABEONA THERAPEUTICS INC. (ABEO) reported Increase (Decrease) in Due to Related Parties of $7.00 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDueToRelatedParties · last filed 2026-05-13
- ABEONA THERAPEUTICS INC. increase (decrease) in due to related parties for the quarter ending 2026-03-31 was $7.00M.
- ABEONA THERAPEUTICS INC. increase (decrease) in due to related parties for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- ABEONA THERAPEUTICS INC. increase (decrease) in due to related parties for the quarter ending 2022-03-31 was -$296.00K, a 120.86% decline year-over-year.
- ABEONA THERAPEUTICS INC. increase (decrease) in due to related parties for the quarter ending 2021-12-31 was -$20.00M.
- ABEONA THERAPEUTICS INC. increase (decrease) in due to related parties for fiscal 2024 was -$5.00M.
- ABEONA THERAPEUTICS INC. increase (decrease) in due to related parties for fiscal 2022 was -$5.00M.
- ABEONA THERAPEUTICS INC. increase (decrease) in due to related parties for fiscal 2021 was -$16.41M.
| Period end | Increase (Decrease) in Due to Related Parties 3 month | Increase (Decrease) in Due to Related Parties 6 month | Increase (Decrease) in Due to Related Parties 9 month | Increase (Decrease) in Due to Related Parties 12 month |
|---|---|---|---|---|
| 2026-03-31 | $7.00M 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | -$5.00M 10-K · filed 2026-03-17 | |||
| 2022-12-31 | -$5.00M 10-K · filed 2024-03-18 | |||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$296.00K 10-Q · filed 2023-08-08 | -$20.30M derived: sum of 3 quarters · filed 2023-08-08 | -$19.63M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$296.00K 10-Q · filed 2023-05-11 | -$20.30M derived: sum of 2 quarters · filed 2023-05-11 | -$19.63M derived: sum of 3 quarters · filed 2023-05-11 | -$18.13M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$20.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$19.33M derived: sum of 2 quarters · filed 2023-03-29 | -$17.83M derived: sum of 3 quarters · filed 2023-03-29 | -$16.41M 10-K · filed 2023-03-29 |
| 2021-09-30 | $669.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $2.17M derived: sum of 2 quarters · filed 2022-11-14 | $3.59M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $2.92M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $1.42M 10-Q · filed 2022-05-13 | |||
| 2020-06-30 | $800.00K 10-Q · filed 2020-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |